According to filings with the U.S. Securities and Exchange Commission, Amydis is raising $9,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Stella Sarraf played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Amydis
Amydis, Inc. is a privately-held pharmaceutical company focused on developing innovative chemistry to detect diseases that involve the presence of amyloid proteins. Our mission is to develop a universal, non-invasive diagnostic that is faster, more accessible, and more affordable than current tests for diseases with unmet clinical and medical needs. Amydis has a platform of novel compounds that fluoresces when bound to amyloid proteins, thus enabling diagnosis of such diseases. The Company’s most advanced program is targeting the detection of early stage Alzheimers disease, a well-known amyloid disease. Other potential development programs include the detection of Parkinsons disease, Creutzfeldt-Jakob disease (mad cow disease), Pre-eclampsia, TTR Amyloidosis, and Cerebral Amyloid Angiopathy, all of which are associated with the presence of amyloid protein.

To learn more about Amydis, visit http://www.amydis.com/

Contact:
Stella Sarraf, Chief Executive Officer
310-229-5710
https://www.linkedin.com/in/stellasarraf/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved